Get started
Author

Charlene Minx

OpenAlex ID: A5054245166
Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2018 · Adam J. Camblin, Emily A. Pace, et al. · Clinical Cancer Research · 58
Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer
2020 · Michelle K. Greene, Ting Chen, et al. · British Journal of Cancer · 19
PDF
Supplemental legend from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Figure S2 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Figure S6 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Figure S4 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Table S1 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Figure S3 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Table S3 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Figure S5 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Table S2 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Figure S1 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Supplemental legend from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Figure S1 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Figure S2 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Figure S3 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Figure S4 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Table S1 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Figure S5 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Figure S6 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Table S3 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Table S2 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Data from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Data from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
2023 · Adam J. Camblin, Emily A. Pace, et al.
Abstract 3704: Efficacy of DR5-targeted immunoliposomes in pancreatic cancer models primed with SMO inhibitors
2018 · Darren Chan, Charlene Minx, et al. · Cancer Research
Works count: 25
Citation count: 77
H-index: 2
I10-index: 2
Year
Topic
Type